GlassScriptPhysician profile
Stephanie M Meyer
NPI 1215148341
$3,171.97
in general payments reported to CMS, 2019-2025
27 companies · $473 in 2025
The $473 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $650 · 2020: $615 · 2021: $203 · 2022: $167 · 2023: $613 · 2024: $450 · 2025: $473.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,460 · Education: $77.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,459.53 |
| Education | $77.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $460.69 | 2019-2025 | Mounjaro, Trulicity, Zepbound |
| Pfizer INC. | $357.08 | 2019-2025 | |
| Abbvie INC. | $237.47 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $227.21 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Otsuka America Pharmaceutical, INC. | $224.85 | 2020-2025 | Rexulti |
| Glaxosmithkline, LLC. | $210.11 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Novo Nordisk INC | $197.68 | 2019-2025 | Ozempic, Rybelsus |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $156.29 | 2019-2024 | Xifaxan |
| Eisai INC. | $141.86 | 2020-2021 | |
| Abbott Laboratories | $130.91 | 2023-2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $125.67 | 2019-2023 | Steglatro, Belsomra |
| Janssen Pharmaceuticals, INC | $120.48 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $112.23 | 2020-2025 | Jardiance |
| Lundbeck LLC | $77.08 | 2025 | Rexulti |
| Allergan, INC. | $71.52 | 2019-2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $60.64 | 2023-2024 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $42.81 | 2019-2020 | |
| Astellas Pharma US INC | $38.75 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $35.36 | 2022-2023 | Eliquis |
| Amarin Pharma, INC. | $31.36 | 2020 | |
| Sanofi-Aventis U.S. LLC | $28.78 | 2019 | |
| Sanofi Pasteur INC. | $17.55 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.66 | 2022 | |
| Cranial Technologies, INC | $14.41 | 2021 | |
| Bausch Health US, LLC | $11.81 | 2020 | |
| Amgen INC. | $11.39 | 2019 | |
| Mylan Specialty L.P. | $11.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Meyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.